Preclinical POC / Pharmacological models
Our proprietary efficacy models resulting from our Research and Development activity are a strategic decision-making support for clinical trials and help bolster regulatory application for IND.
Our translational non-human primate models are well suited for Proof of Concept (POC) studies in several therapeutic areas critical for Human health.
To achieve high quality efficacy studies, we combine outstanding scientific knowledge, an in-depth expertise of the model, state-of-the-art technics, relevant clinical endpoints, robust study design, with a GLP-like data analysis, SOP and reporting.
The study parameters are customized to each project and goal, from the sampling method to the types of in vivo and ex vivo investigations.
To address particular issues relevant to drugs MOA, we can refine the characterization of our models based on the sponsor’s need, or even combine several models.
Due to our extensive knowldege of this in vivo model and our experience of over 15 years, we can also develop custom-made efficacy models. Contact us to discuss your needs.
Infectious diseases
Respiratory infectious diseases
- Viral respiratory infections including SARS-CoV-2 model
- Respiratory bacterial infections
Infectious diseases
- Tropical diseases
- Parasitic infections
- Viral/bacterial co-infection
Other therapeutic areas
Cardiometabolic diseases
- Post-ischemic heart failure
- Diet-induced atherosclerosis
Bone & musculoskeletal diseases
- Post-traumatic Osteoarthritis model
- Cartilage defect
The study parameters are adapted to each project and goal, from the ROA, sampling method to the types of in vivo and ex vivo investigations and bioanalysis.
To address particular issues relevant to patients, we can refine the characterization of our models based on the sponsor’s need, or combine several models.
